Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optomedic Medical Technologies

This article was originally published in The Gray Sheet

Executive Summary

Israel-based company plans to use $1.5 mil. of an anticipated $9.6 mil. initial public offering of 2.25 mil. ordinary shares at $5 per share to develop a prototype model of the CardioLaser CO2-based transmyocardial revascularization laser ablation system. The company is earmarking an additional $1 mil. for other R&D projects, $2 mil. to pay down outstanding debt, roughly $1.3 mil. to pay obligations to certain officers and 10%-or-greater shareholders, $1.5 mil. to enhance marketing efforts, $500,000 for manufacturing purposes and $1.9 mil. for working capital and general corporate expenses. The TMR laser is based on the firm's Kaplan PenduLaser 115 CO2 system, which has been sold outside the U.S. since late 1994 and domestically since the third quarter of 1997; the device gained 510(k) clearance in March 1995 for general surgery applications ("The Gray Sheet" April 17, 1995, p. 9). Potential future applications include aesthetic, general, dental and oral, gynecological, ear nose and throat and periocular surgery procedures, the firm states. Founded in 1992, the company generated $1.1 mil. in sales in the fiscal year ending Dec. 31, 1997, up 12%. The company reported a net loss of $3.2 mil. for the year. Underwriters M.H. Meyerson & Co. have the option to purchase 337,500 additional IPO shares
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel